Group 2 included naïve CD4+ T cells incubated with TDEs from MT KRAS NSCLC cells, and Group 3 included enriched Tregs isolated from donor PBMCs served as a positive control. The gene discussed is CD4; the disease is non-small cell lung carcinoma.